All Oncology News

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

Nogapendekin alfa inbakicept MAAs have been submitted to the EU's EMA and the UK's MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.

OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.

An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.

The xT CDx assay is now available nationwide in the United States for use in solid tumor profiling.

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.

Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.